Zhijun Wu1, Min Xu1, Haihui Sheng2, Yuqing Lou3, Xiuxiu Su1, Yanjia Chen1, Lin Lu1, Yan Liu1, Wei Jin1. 1. Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China. 2. National Engineering Center for Biochip at Shanghai Shanghai, China. 3. Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University Shanghai, China.
Abstract
BACKGROUND: Left ventricular dysfunction (LVD) occurs with myocardial ischemia and coronary artery disease (CAD). The natriuretic peptide system has compensatory vasodilatory, natriuretic and paracrine effects on LVD and subsequent heart failure. The aim of this study was to investigate the relationship between natriuretic peptide polymorphisms and risk of LVD in CAD patients. METHODS: We recruited 747 consecutive Southern Han Chinese patients with angiographically confirmed CAD, 201 had a reduced left ventricle ejection fraction (LVEF ≤45%, LVD group) and 546 had a preserved left ventricle ejection fraction (LVEF >45%). The reduced and preserved LVEF groups were matched by gender and age. Taqman assays were performed to identify five polymorphisms in the NPPA-NPPB locus (rs5065, rs5063, rs632793, rs198388 and rs198389). RESULTS: Single-locus analyses found no significant difference in the allele and genotype frequencies of the reduced and preserved LVEF group, even after adjusting for confounding factors. Subgroup analyses performed by hyperlipidemia (HLP) demonstrated 3 polymorphisms, rs632793 (OR = 0.31, 95% CI 0.1-0.93, P = 0.04), rs198388 (OR = 0.26, 95% CI 0.09-0.79, P = 0.02) and rs198389 (OR = 0.26, 95% CI 0.09-0.80, P = 0.02) were associated with the reduced risk of LVD. No CAD-susceptible haplotypes were identified. Multifactor dimensionality reduction analysis did not detect any gene-to-gene interactions among the five loci. Three loci (rs5063, rs632793 and rs198388) formed the best model with the maximum testing accuracy (39.89%) and cross-validation consistency (10/10). CONCLUSION: Three NPPA-NPPB polymorphisms (rs632793, rs198388 and rs198389) were associated with reduced risk of LVD in CAD patients with HLP.
BACKGROUND:Left ventricular dysfunction (LVD) occurs with myocardial ischemia and coronary artery disease (CAD). The natriuretic peptide system has compensatory vasodilatory, natriuretic and paracrine effects on LVD and subsequent heart failure. The aim of this study was to investigate the relationship between natriuretic peptide polymorphisms and risk of LVD in CAD patients. METHODS: We recruited 747 consecutive Southern Han Chinese patients with angiographically confirmed CAD, 201 had a reduced left ventricle ejection fraction (LVEF ≤45%, LVD group) and 546 had a preserved left ventricle ejection fraction (LVEF >45%). The reduced and preserved LVEF groups were matched by gender and age. Taqman assays were performed to identify five polymorphisms in the NPPA-NPPB locus (rs5065, rs5063, rs632793, rs198388 and rs198389). RESULTS: Single-locus analyses found no significant difference in the allele and genotype frequencies of the reduced and preserved LVEF group, even after adjusting for confounding factors. Subgroup analyses performed by hyperlipidemia (HLP) demonstrated 3 polymorphisms, rs632793 (OR = 0.31, 95% CI 0.1-0.93, P = 0.04), rs198388 (OR = 0.26, 95% CI 0.09-0.79, P = 0.02) and rs198389 (OR = 0.26, 95% CI 0.09-0.80, P = 0.02) were associated with the reduced risk of LVD. No CAD-susceptible haplotypes were identified. Multifactor dimensionality reduction analysis did not detect any gene-to-gene interactions among the five loci. Three loci (rs5063, rs632793 and rs198388) formed the best model with the maximum testing accuracy (39.89%) and cross-validation consistency (10/10). CONCLUSION: Three NPPA-NPPB polymorphisms (rs632793, rs198388 and rs198389) were associated with reduced risk of LVD in CAD patients with HLP.
Authors: Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams Journal: Circulation Date: 2009-11-18 Impact factor: 29.690
Authors: N Tamura; Y Ogawa; H Chusho; K Nakamura; K Nakao; M Suda; M Kasahara; R Hashimoto; G Katsuura; M Mukoyama; H Itoh; Y Saito; I Tanaka; H Otani; M Katsuki Journal: Proc Natl Acad Sci U S A Date: 2000-04-11 Impact factor: 11.205
Authors: M Adnan Nadir; Eleanor Dow; John Davidson; Norman Kennedy; Chim C Lang; Allan D Struthers Journal: Eur J Heart Fail Date: 2013-12-03 Impact factor: 15.534
Authors: Fabiola Del Greco M; Cristian Pattaro; Andreas Luchner; Irene Pichler; Thomas Winkler; Andrew A Hicks; Christian Fuchsberger; Andre Franke; Scott A Melville; Annette Peters; H Erich Wichmann; Stefan Schreiber; Iris M Heid; Michael Krawczak; Cosetta Minelli; Christian J Wiedermann; Peter P Pramstaller Journal: Hum Mol Genet Date: 2011-01-27 Impact factor: 6.150
Authors: Sara B Seidelmann; Orly Vardeny; Brian Claggett; Bing Yu; Amil M Shah; Christie M Ballantyne; Elizabeth Selvin; Calum A MacRae; Eric Boerwinkle; Scott D Solomon Journal: J Am Heart Assoc Date: 2017-03-24 Impact factor: 5.501